{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:21:16Z","timestamp":1795022476674,"version":"4.10.1"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"43","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,24]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Managing type 2 diabetes mellitus (T2DM) in adults with severe obesity frequently coexists with obstructive sleep apnea (OSA), complicating metabolic control and quality of life. Real-world, objective monitoring\u2013documented trajectories through which pharmacologic weight loss enables withdrawal of continuous positive airway pressure (CPAP) remain clinically informative.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 48-year-old man (height 178\u2009cm; weight 129\u2009kg; BMI 40.7\u2009kg\/m\u00b2) had T2DM and severe OSA diagnosed by polysomnography (PSG), with persistent daytime sleepiness despite CPAP and body-weight fluctuations between 108 and 129\u2009kg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>T2DM with class III obesity and severe OSA with prior peak HbA1c of 8.2%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Beginning in June 2023, tirzepatide was initiated with gradual dose escalation alongside nutritional counseling and light-to-moderate physical activity. At initiation, it was prescribed for glycemic control and weight reduction in T2DM and thus predated the subsequent U.S. FDA approval for OSA. OSA outcomes were later assessed with objective monitoring via CPAP telemonitoring as part of routine comorbidity care. CPAP was continued initially and reassessed after weight loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Within 3 months, weight decreased to 108\u2009kg (BMI 34.1\u2009kg\/m\u00b2) with improved glycemic control. On CPAP telemonitoring, the device-derived residual apnea\u2013hypopnea index decreased and remained low over time. Given sustained weight loss and improved symptoms, CPAP was discontinued under supervision. At the most recent follow-up, the patient weighed 82\u2009kg (BMI 25.9\u2009kg\/m\u00b2) and reported improved daytime functioning. No severe adverse events occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>In selected adults with T2DM and OSA, tirzepatide-associated weight loss may contribute to device-monitored control of OSA on CPAP, enabling supervised withdrawal in carefully selected cases. While single-patient observations cannot establish causality, they complement emerging evidence and can guide patient counseling and hypothesis generation for prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000045445","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T19:02:29Z","timestamp":1761332549000},"page":"e45445","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Tirzepatide-induced weight loss and obstructive sleep apnea improvement in an adult with type 2 diabetes: A case report"],"prefix":"10.1097","volume":"104","author":[{"given":"Noriko","family":"Funamizu","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hirose Hospital (Ehime), Imabari-City, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6076-6516","authenticated-orcid":false,"given":"Naotake","family":"Funamizu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hirose Hospital (Ehime), Imabari-City, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunemichi","family":"Hirose","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hirose Hospital (Ehime), Imabari-City, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261118","doi-asserted-by":"crossref","first-page":"e1501332","DOI":"10.1126\/sciadv.1501332","article-title":"Obesity-induced DNA released from adipocytes stimulates chronic adipose tissue inflammation and insulin resistance.","volume":"2","author":"Nishimoto","year":"2016","journal-title":"Sci Adv"},{"key":"R2-20261118","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.sleep.2024.09.013","article-title":"Obstructive sleep apnea comorbid with insomnia symptoms and objective short sleep duration is associated with clinical and preclinical cardiometabolic risk factors: clinical implications.","volume":"124","author":"Pejovic","year":"2024","journal-title":"Sleep Med"},{"key":"R3-20261118","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.3390\/nu16244255","article-title":"Effects of a one-year intensified weight loss program on body composition parameters in patients with severe obesity and Obstructive Sleep Apnea (OSA): a randomized controlled trial.","volume":"16","author":"Miralles-Llum\u00e0","year":"2024","journal-title":"Nutrients"},{"key":"R4-20261118","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 Receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes.","volume":"106","author":"Thomas","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"R5-20261118","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity.","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"R7-20261118","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/MS9.0000000000002975","article-title":"Tirzepatide: a dual-action solution for obstructive sleep apnea and obesity.","volume":"87","author":"Afridi","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"key":"R8-20261118","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R9-20261118","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/dom.15312","article-title":"Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in japanese patients with type 2 diabetes mellitus.","volume":"26","author":"Tsukamoto","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"R10-20261118","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity.","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"R11-20261118","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/dom.16059","article-title":"The cumulative impact of type 2 diabetes and obstructive sleep apnoea on cardiovascular, liver, diabetes-related and cancer outcomes.","volume":"27","author":"Riley","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"R12-20261118","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.chest.2017.05.009","article-title":"Obstructive sleep apnea and diabetes: a state of the art review.","volume":"152","author":"Reutrakul","year":"2017","journal-title":"Chest"},{"key":"R13-20261118","doi-asserted-by":"crossref","first-page":"215","DOI":"10.5664\/jcsm.27489","article-title":"Prevalence of type 2 diabetes in patients with obstructive sleep apnea in a multi-ethnic sample.","volume":"5","author":"Mahmood","year":"2009","journal-title":"J Clin Sleep Med"},{"key":"R14-20261118","first-page":"43","article-title":"Comparison of the risk factors for obstructive sleep apnoea between type 1 and type 2 diabetes patients: a cross-sectional study using the diabetes study from the Center of Tokyo Women\u2019s Medical University (DIACET).","volume":"3","author":"Shen","year":"2019","journal-title":"Tokyo Womens Med Univ J"},{"key":"R15-20261118","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1507\/endocrj.EJ17-0356","article-title":"Association between severity of obstructive sleep apnea and glycated hemoglobin level in Japanese individuals with and without diabetes.","volume":"65","author":"Kurosawa","year":"2018","journal-title":"Endocr J"},{"key":"R16-20261118","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/14656566.2024.2437525","article-title":"Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review.","volume":"26","author":"El-Solh","year":"2025","journal-title":"Expert Opin Pharmacother"},{"key":"R17-20261118","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1164\/rccm.201903-0692OC","article-title":"Effect of weight loss on upper airway anatomy and the apnea\u2013hypopnea index.","volume":"201","author":"Wang","year":"2020","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:01:43Z","timestamp":1795021303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":16,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045445","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"2025-06-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}